Literature DB >> 18990746

Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Jonathan L Hecht1, Joanne Kotsopoulos, Margaret A Gates, Susan E Hankinson, Shelley S Tworoger.   

Abstract

BACKGROUND: Tissue microarrays (TMAs) allow high-throughput evaluation of protein expression from archived tissue samples. We identified characteristics specific to ovarian cancer that may influence TMA interpretation.
METHODS: TMAs were constructed using triplicate core samples from 174 epithelial ovarian cancers. Stains for p53, Ki-67, estrogen receptor-alpha, progesterone receptor, Her-2, WT-1, cytokeratin 7, and cytokeratin 20 were evaluated by intraclass correlation coefficients, Spearman correlation coefficients, the effect of sample age, and tumor histology on the ability to score the cores, and inter-rater reliability.
RESULTS: The interclass correlation coefficient and the mean Spearman correlation coefficients among 3 cores were > or = 0.91 and 0.87, respectively. Tissue age and tumor histology were not predictive of an inability to evaluate stains, but borderline tumors had a 2 to 4-fold increase in the risk of having uninterpretable cores over invasive tumors. There was moderate to substantial concordance between the two pathologists for estrogen receptor-alpha [Cohen's Kappa (kappa), 0.79] and Ki-67 (kappa, 0.52). The prevalence of positive staining cells by histologic type was comparable with previous studies.
CONCLUSION: TMA is a valid method for evaluating antigen expression in invasive ovarian cancer but should be used with caution for borderline tumors. We suggest several methods of quality control based on intercore comparisons and show that some antigens may be affected by age of the samples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990746      PMCID: PMC2628443          DOI: 10.1158/1055-9965.EPI-08-0645

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

Review 1.  Amplification of tissue by construction of tissue microarrays.

Authors:  D L Rimm; R L Camp; L A Charette; D A Olsen; E Provost
Journal:  Exp Mol Pathol       Date:  2001-06       Impact factor: 3.362

2.  Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases.

Authors:  Russell Vang; Allen M Gown; Todd S Barry; Darren T Wheeler; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2006-01       Impact factor: 7.842

3.  Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.

Authors:  Peng Lee; Daniel G Rosen; Changcheng Zhu; Elvio G Silva; Jinsong Liu
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

4.  Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?

Authors:  A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson
Journal:  J Clin Oncol       Date:  2006-03-27       Impact factor: 44.544

5.  Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.

Authors:  P Muti; H L Bradlow; A Micheli; V Krogh; J L Freudenheim; H J Schünemann; M Stanulla; J Yang; D W Sepkovic; M Trevisan; F Berrino
Journal:  Epidemiology       Date:  2000-11       Impact factor: 4.822

Review 6.  The Nurses' Health Study: lifestyle and health among women.

Authors:  Graham A Colditz; Susan E Hankinson
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

7.  Validation of tissue microarray technology in breast carcinoma.

Authors:  R L Camp; L A Charette; D L Rimm
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

8.  Validation of tissue microarray technology in ovarian carcinoma.

Authors:  Daniel G Rosen; Xuelin Huang; Michael T Deavers; Anais Malpica; Elvio G Silva; Jinsong Liu
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

9.  Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Authors:  Estrid V S Høgdall; Lise Christensen; Claus K Høgdall; Jan Blaakaer; Simon Gayther; Ian J Jacobs; Ib Jarle Christensen; Susanne K Kjaer
Journal:  Oncol Rep       Date:  2007-11       Impact factor: 3.906

Review 10.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

View more
  11 in total

1.  Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.

Authors:  Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-13       Impact factor: 4.254

2.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

3.  Tissue microarrays: one size does not fit all.

Authors:  Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon
Journal:  Diagn Pathol       Date:  2010-07-07       Impact factor: 2.644

4.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

5.  Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

6.  TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?

Authors:  Mamta Gupta; Ana Babic; Andrew H Beck; Kathryn Terry
Journal:  Hum Pathol       Date:  2016-04-08       Impact factor: 3.466

7.  Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.

Authors:  Mollie E Barnard; Alexander Pyden; Megan S Rice; Miguel Linares; Shelley S Tworoger; Brooke E Howitt; Emily E Meserve; Jonathan L Hecht
Journal:  Gynecol Oncol       Date:  2018-07-09       Impact factor: 5.482

8.  Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors.

Authors:  Joanne Kotsopoulos; Jonathan L Hecht; Jonathan D Marotti; Linda E Kelemen; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

9.  Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.

Authors:  Mollie E Barnard; Jonathan L Hecht; Megan S Rice; Mamta Gupta; Holly R Harris; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-30       Impact factor: 4.254

10.  Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker.

Authors:  Massimo Mascolo; Gennaro Ilardi; Francesco Merolla; Daniela Russo; Maria Luisa Vecchione; Gaetano De Rosa; Stefania Staibano
Journal:  Int J Mol Sci       Date:  2012-09-05       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.